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Objectives.Toevaluatewhetherthereareanydemographicorurodynamicdiﬀerencesinpatientswithidiopathicoveractivebladder
(I-OAB) that respond and do not respond to intradetrusor injections of botulinum toxin-A (BTX-A). Methods. This represents
a secondary analysis of data collected from an investigator initiated randomized trial designed to evaluate clinical diﬀerences
in outcomes for 100 versus 150 U BTX-A in patients with I-OAB. Preinjection demographic and urodynamic data were collected.
Patients were evaluated 12 weeks after injection and were determined to be responders or nonresponders as deﬁned by our criteria.
Statistical comparisons were made between groups. Results. In patients with overactive bladder without incontinence (OAB-Dry),
there were no variables that could be used to predict response to BTX-A. On univariate analysis, younger patients with overactive
bladder with incontinence (OAB-Wet) were more likely to respond to BTX-A than older patients. However, this relationship was
no longer statistically signiﬁcant on multivariate analysis. Conclusions. We were unable to identify any preinjection demographic
or urodynamic parameters that could aid in predicting which patients will achieve clinical response to BTX-A. Future studies are
necessary to further evaluate this question.
Copyright © 2009 Brian L. Cohen et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
I-OAB is a highly prevalent condition in both the United
States and Europe with millions of adults being aﬀected
by the disorder [1]. Oral antimuscarinic agents have been
the mainstay of treatment for patients with I-OAB; however
they are associated with a high discontinuation rate either
due to intolerable side eﬀects or lack of eﬃcacy. Alternative
therapies in the form of sacral neuromodulation and more
recently intradetrusor BTX-A injection are now becoming
attractive alternatives for patients failing oral medications.
As newer surgical treatment options become available,
improved understanding of both the mechanism of action
and the ideal patient for each treatment is paramount
considering the cost involved. Currently, little is known
concerning the ability to predict which patients will or
will not respond to sacral neuromodulation [2], and even
less is known about which patient will respond to BTX-
A therapy [3–5]. Therefore, we conducted a secondary
analysis of patients enrolled in a prospective randomized
trial comparing 2 doses of intradetrusor BTX-A therapy
for I-OAB in order to determine any demographic or
urodynamic (UDS) parameters that may assist in predicting
which patients will respond to BTX-A.
2.MaterialsandMethods
Thisstudyisasecondaryanalysisfromanongoing,investiga-
tor initiated, IRB-approved, randomized, prospective study
to evaluate symptomatic and UDS improvement in patients
with I-OAB receiving either 100 or 150 U of BTX-A (Botox,
Allergan, Irvine, Calif, USA).
From January 2002 until January 2008, 47 patients with
I-OAB were randomized to receive either 100 or 150U of
BTX-A at a single center. All patients signed an informed
consent prior to study enrollment. The study protocol has
been approved by our Institutional Review Board.
Patients with I-OAB as deﬁned by the International
Continence Society (ICS) were eligible for the study [6], and
UDS demonstration of detrusor overactivity (DO) was not a
requirement for study eligibility. Patients were subclassiﬁed
into 2 groups: OAB-Wet and OAB-dry. As per a three-day2 Advances in Urology
voiding diary (3-VD), patients with urgency and frequency
ofurination(>8voidsperday)withatleastonedailyepisode
of urge urinary incontinence (UUI) were included within
the OAB-wet group. OAB-Dry patients had urinary urgency,
frequency >8 voids per day, and no complaint of UUI as
documented by 3-VD. Subjects were required to have either
failed or have been unable to tolerate treatment with at
least 2 diﬀerent antimuscarinic agents and have been treated
with these agents for at least 2 months prior to enrollment.
Subjects were required to discontinue all medications that
could interfere with urethrovesical function 4 weeks prior to
the ﬁrst BTX-A injection.
Patients with a history of renal impairment, myasthenia
gravis, neurogenic bladder dysfunction, bladder or kidney
tumor, serious medical comorbidity, and pregnant or breast-
feeding women were excluded from the study. Additionally,
patients with bladder outlet obstruction as deﬁned by a
pressure-ﬂow urodynamic study, patients with a postvoid
residual (PVR) >100mL, and patients with demonstrable
stress urinary incontinence either by exam or on UDS were
excluded from the study. Obstructive voiding on UDS was
determined by the ICS nomogram for men only. All men
with obstructive voiding were excluded. For women, we used
the Blaivas-Groutz nomogram and classiﬁed obstructive
voiding as a maximal detrusor pressure at maximum ﬂow
(pDetQMax) of ≥20cm H2O and a maximal free ﬂow rate
(Qmax) of <12mL/s [7].
All study subjects underwent a complete history and
physical examination, multichannel video urodynamics, and
completed a 3-VD prior to study enrollment. Urinary
frequency (UF), UUI episodes, and volume voided were
collected from the 3-VD. Baseline laboratory evaluation
included a basic metabolic panel, urinalysis, and urine
culture. When documented, urinary tract infections were
treated and sterile urine cultures were documented prior to
study enrollment. Urinalysis, urine culture, PVR, 3-VD data,
and adverse events were obtained at clinic visits at 2, 6, 12,
and 24 weeks postinjection.
Our injection technique is well tolerated and has been
previously reported [8]. Brieﬂy, subjects were injected in
an oﬃce setting after the bladder was instilled with 40mL
of 1% lidocaine solution using a 14 French urethral Foley
catheter. After 15 minutes, an Olympus 14 French ﬂexible
cystoscope was introduced into the bladder. The bladder
was then distended with 100–200mL of 0.9% normal
saline. Using a 27-guage ﬂexible Olympus injection needle
(1050mm working length with a 4mm needle length), the
supratrigonal detrusor muscle was injected with BTX-A
10units/mL in 10–15 separate sites using 1mL for each
injection site. A prophylactic antibiotic was prescribed for 3
days postinjection. All subjects voided prior to discharge.
Primary outcome analysis focused on data from the 3-
VD. UF is the dominant symptom in the OAB-Dry group
and was calculated from the average number of daily voids
recorded from the 3-VD. We considered a 40% reduction in
UF to be a positive clinical response. UUI is the dominant
symptomintheOAB-Wetgroupandwascalculatedfromthe
average number of daily incontinence episodes recorded on
the 3-VD. We considered a 50% reduction in UUI episodes
to be a positive clinical response. Preinjection demographic
and UDS parameters were compared within groups using
aS t u d e n t ’ st-test for continuous variables and Chi square
analysis for discontinuous variables with a signiﬁcance level
of α<0.05.
3. Results and Discussion
Of the 20 patients in the OAB-Dry group injected with BTX-
A, 15 were responders and 5 were considered nonresponders.
Ofthe27patientsintheOAB-Wetgroup,17wereconsidered
respondersand10wereconsiderednonresponders. Amongst
OAB-Wet patients, there was a statistically signiﬁcant dif-
ference in age between the responders and nonresponders.
There were no statistically signiﬁcant diﬀerences noted
between responders and nonresponders in regards to dose of
BTX-A received, patient sex, nor any of the measured UDS
parameters (Table 1).
On univariate analysis, patients with both OAB-dry and
OAB-wet who responded to the therapy were found to be
younger than those that did not achieve clinical response
(55 ± 1 5y e a r sv e r s u s6 8± 13 years, P = .03). No UDS
parameters were useful for prediction of clinical response
althoughresponderstendedtohavehighermaximaldetrusor
pressure (49±24 versus 29±16cm H2O, P = .06) (Table 1).
When these variables were placed in a logistic regression
model for multivariate analysis, neither were signiﬁcantly
associated with response to BTX-A injection (P = .14 for
pDetMax and P = .13 for age).
As little as 10 years ago, patients with I-OAB had few
options for treatment with only 2 available medications
and no surgical options. As both the general public and
practitioners become more aware of OAB and the potential
impact on quality of life, more and more patients are
seeking care for this condition. For patients that fail medical
therapy, sacral neuromodulation and increasingly BTX-A
therapy are becoming viable options. With more options
availablefortreatmentofOABthaneverbefore,animproved
understanding of an individual’s likelihood of responding
to a given therapy will not only improve patient care but
also decrease the expense of failing other costly therapies.
Withthisinmind,wehaveperformedthissecondaryanalysis
of our data from an ongoing clinical trial comparing 2
doses of BTX-A therapy in patients with I-OAB in order to
improve the understanding of who is more likely to respond
to intradetrusor BTX-A.
When analyzing our 2 subgroups in this study cohort,
we were unable to identify any demographic or urodynamic
parameters that predicted response in the OAB-Dry patients,
andwefoundthatyoungerpatientswithincontinence(OAB-
Wet)weremorelikelytorespond.Althoughitdidnotachieve
statistical signiﬁcance, those with higher pDetMax tended to
respond better than those with lower pressures (P = .06).
However, in a multivariate model, no signiﬁcant predictors
for response could be identiﬁed.
Few other investigators have performed similar evalua-
tionsoftheirdata.Intheirreportoftheﬁrst100patientswith
I-OAB injected with 100 U BTX-A, Schmid et al. found that
poor compliance, maximal cystometric capacity <100mL,Advances in Urology 3
Table 1: Comparison of responders and nonresponders in patients with OAB-Dry and OAB-Wet: demographic and urodynamic data.
OAB-DRY OAB-WET
Parameter (units) Responders Nonresponders P-value Responders Nonresponders P-value
N 15 5 NA 17 10 NA
PVR (mL) 24 ± 36 29 ±36 .76 24 ±25 24 ±33 .93
MCC (mL) 242 ± 112 263 ±124 .66 248 ±147 227 ±100 .71
pDetMax (cm H2O) 40 ± 17 34 ±18 .47 49 ±24 29 ±16 .06
pVesMax (cm H2O) 62 ± 27 51 ±12 .38 74 ±32 60 ±30 .24
Voided vol (mL) 279 ± 148 226 ±174 .51 223 ±155 171 ±97 .24
pDetQMax (cm H2O) 24 ± 12 43 ±48 .58 35 ±20 23 ±20 .23
QM a x( m L / s e c ) 1 4±61 3 ±11 .91 15 ±11 14 ±7. 9 9
DO+ 5/15 1/5 .58 12/17 8/10 .99
100 Units 6 4 .15 84 .77
150 Units 9 1 11 4
Age 48 ± 15 59 ±13 .11 55 ±15 68 ±13 .03
Number of males 5 0 .20 1 0 .89
PVR: postvoid residual; MCC: maximum cystometric capacity; pDetMax: detrusor maximum pressure; pVesMax: vesical maximum pressure; vol: volume;
Qmax: maximum ﬂow rate; DO+: presence of detrusor overactivity; mL: milliliters; cm H2O: centimeters of water; mL/sec: milliliters per second.
and bladder wall ﬁbrosis on biopsy portended poor response
to BTX-A [3]. In a study of patients with neurogenic OAB
receiving 300U BTX-A, no diﬀerences were found between
the responders and nonresponders concerning clinical and
urodynamic data [5]. Those that responded to the therapy
tended to have a lesser degree of bladder wall ﬁbrosis, but
this did not achieve statistical signiﬁcance. Finally, Sahai
et al. evaluated 33 patients with idiopathic OAB receiving
200U of BTX-A and identiﬁed 5 patients who had a poor
response [4]. These investigators found that poor responders
had signiﬁcantly higher maximal detrusor pressures during
detrusor overactivity, and all other investigated parameters
were similar. However, the information in this study may be
confounded by the fact that 45% of the patients continued
to take anticholinergic medication at the time of injection,
and 30% continued their medication 6 months after the
injection. We believe further studies with a larger cohort of
patients are required to precisely predict the responders and
nonresponders for BTX-A therapy.
4. Conclusions
BTX-A therapy is becoming increasingly popular for the
management of I-OAB in patients who have failed medical
therapy. As more options become available for the treatment
of this condition, being able to predict which therapy will
provide an individual with the best chance of response will
be clinically and economically beneﬁcial. The present study
suggests that demographic and urodynamic data are not
helpful for determining who will and will not respond to
BTX-A therapy. Additional investigation into this matter is
important and will add valuable information concerning the
treatment of I-OAB with BTX-A.
In addition, prospective randomized study powered to
detect predictors of response to Botox will have signiﬁcant
clinical applications. Our study represents one of the ﬁrst
evertoinvestigatepredictorsofasuccessfulresponsetoBTX-
A patients in idiopathic OAB.
Abbreviations
BTX-A: Botulinum toxin-A
I-OAB: Idiopathic overactive bladder
ICS: International Continence Society
OAB-Dry: Overactive bladder without incontinence
OAB-Wet: Overactive bladder with incontinence
3-VD: 3 day voiding diary




MCC: Maximal cystometric capacity
pDetMax: Maximal detrusor pressure
pVesMax: Maximal vesical pressure
pDetQMax: Detrusor pressure at maximal ﬂow
QMax: Maximal ﬂow rate
DO: Detrusor overactivity.
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